Meitar represented Endemol Group, the world’s largest independent production company in its investment in Reshet, one of Israel’s leading broadcasters. Endemol acquired 33% of Reshet for NIS 100 million and entered into a strategic partnership with Reshet. The transaction, which required regulatory approvals (broadcasting and antitrust), closed in April 2014.
Our firm represented Barclays and several other underwriters in the $41 million initial public offering of ADSs by Mazor Robotics Ltd. on NASDAQ.
Our law firm was recently ranked by Globes and Dun 100’s as one of the leading law firms in Israel. The firm was ranked as and one of the leading specialists in all of our areas of activity (20 different practice areas!), with all major practice areas of the firm ranked in tier 1:
Mergers & Acquisitions, High-Tech , Project Finance & Infrastructure, International Commercial, Banking and Financing, Commercial Litigation, Class Actions, Venture Capital, Administrative Law, Tax Law, Antitrust, Capital Market, Investment Funds, Municipal Authorities, Intellectual Property and more…
These rankings once again confirm our status as the leading commercial law firm in Israel.
For the full ranking in Hebrew, please click here.
“It is nice to be ‘at the top,’” said partner Dan Geva, when the Globes Dun’s 100 rankings were made public. “But ‘size’ is just a means to an end. Our goal is, and always has been, to be number one in terms of quality, personal service, teamwork and forgoing long-term client relationships. With that comes size. But this is just an added benefit that comes from growing into to be one of the best firms in the country.”
For the full article in Hebrew,
Meitar Represented PrimeSence, 3D sensing technology developer company, in its acquisition by a multinational corporation.
The full update is available through the PDF icon.
Taxation Meitar represented NYSE-listed Covidien, a US medical device manufacture, in its acquisition of Given Imaging, a medical technology company that develops and manufactures the swallowable imaging capsules for endoscopy, for approximately $1 billion.
